Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM8 | O00222 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330357 | 0.86 | PLG (0.42) | SMN1; SMN2CYP2D6LMNAGAA | |
| SCHEMBL26351384 | 0.86 | GRM2 (0.36) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL16049158 | 0.86 | GRM2 (0.36) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL19386548 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL17586745 | 0.81 | SMN1; SMN2 (0.37) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL16237715 | 0.79 | EPHX2 (0.36) | TDP1GRM2GRM3GRM4CYP1A2 | |
| SCHEMBL3543659 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2KMT2AKDM4EMAPTATM | |
| SCHEMBL18691840 | 0.77 | EPHX2 (0.35) | TDP1GRM2GRM3GRM4CYP1A2 | |
| SCHEMBL18199 | 0.77 | TSHR (0.45) | SMN1; SMN2KDM4ETDP1GRM2GRM3 | |
| SCHEMBL167272 | 0.75 | EPHX2 (0.34) | TDP1GRM2GRM3GRM4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499097-A1 | METHODS OF TREATING A SUBJECT FOR POST-TREATMENT LYME DISEASE (PTLD) AND COMPOSITIONS FOR USE IN THE SAME | IncellDx, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| WO-2023192360-A1 | METHODS OF TREATING A SUBJECT FOR POST-TREATMENT LYME DISEASE (PTLD) AND COMPOSITIONS FOR USE IN THE SAME | INCELLDX, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| EP-2867227-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-21 | — | — | EP | claimed |
| EP-2229383-B1 | ISOXAZOLO-PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9487483-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2016-11-08 | — | — | US | claimed |
| US-9428456-B2 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2016-08-30 | — | — | US | claimed |
| US-20150336893-A1 | 1-[m-Carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | claimed |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-28 | — | — | US | claimed |
| EP-2867227-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | claimed |
| EP-2864315-A2 | 1-[M-CARBOXAMIDO(HETERO)ARYL-METHYL]-HETEROCYCLYL-CARBOXAMIDE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2015-04-29 | — | — | EP | claimed |
| CN-101287708-A | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) | PFIZER PROD INC (US) | 2008-10-15 | — | — | CN | claimed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | claimed |
| US-20080139846-A1 | New Process 298 | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | claimed |
| EP-1910304-A2 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | claimed |
| WO-2008026986-A1 | A PROCESS FOR PRODUCING [(4,4- DIF LUOROCYCLOHEXYL) METHYL] AMINE | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | WO | claimed |
| EP-1831177-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | claimed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | claimed |
| CN-1830445-A | Tropane derivatives having therapy using, compounds and polymorph thereof | PFIZER (US) | 2006-09-13 | — | — | CN | claimed |
| WO-2006067443-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139846-A1 | New Process 298 | MRPL21, CDK1, CYP4B1 | SMN1; SMN2 2110/4885KMT2A 2413/4885KDM4E 1765/4885 |
| US-20150148349-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | SMN1; SMN2 3448/4885KMT2A 4715/4885KDM4E 4095/4885 |
| US-20150336893-A1 | 1-[m-Carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide Derivatives | CXCR1, CXCR5, CXCR4 | SMN1; SMN2 3582/4885KMT2A 1644/4885KDM4E 1869/4885 |
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | SMN1; SMN2 552/4885KMT2A 2456/4885KDM4E 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.